Invasive lobular carcinoma (ILC) research and the Lobular Breast Cancer Alliance (LBCA) will both have a presence at this year’s San Antonio Breast Cancer Symposium (SABCS).  SABCS 2021 will feature multiple posters focusing on lobular breast cancer research. These include an abstract and poster submitted by the LBCA, a Spotlight Poster Discussion Session focusing on clinical translational updates in ILC, and posters submitted by members of the LBCA Scientific Advisory Board (SAB). SAB members are highlighted in bold blue font in the list of poster authors below.

The LBCA will also sponsor a session at SABCS focusing on advances in key areas and in technologies available for translational research titled Artificial Intelligence: Beyond the Soundbites. This educational session takes place on Tuesday, December 7 from 5pm-7pm CT.

Lobular Breast Cancer Alliance Poster

Poster Session 3 – Thursday, December 9, 2021: 7:00 am – 8:30 am CT

P3-15-03 Imaging and invasive lobular carcinoma: A survey study conducted by the Lobular Breast  Cancer Alliance

Laurie B Hutcheson1, Janice Axelrod1, Colleen L Fitzwater1, Maxine S Jochelson2, Gitte H Joergensen1, Theresa Langdon1, Julia K Levine1, Otto Metzger3, Mason Mitchell-Daniels1 and Barbara F Neilsen1. 1Lobular Breast Cancer Alliance, Calabasas, CA;2Memorial Sloan Kettering Cancer Center, New York, NY;3Dana-Farber Cancer Institute, Boston, MA 

LBCA Executive Director Laurie Hutcheson will be presenting this poster live in San Antonio (Hall 1) while COO/Volunteer Coordinator Mason Mitchell-Daniels will be presenting virtually.

Spotlight Poster Discussion Session: Clinical Translational Updates in Invasive Lobular Carcinoma

Friday, December 10, 7 am – 8:30am CT/8am – 9:30am ET 

PD14-01 Comprehensive molecular characterization of patients with metastatic invasive lobular carcinoma (ILC): Using real-world data to describe this unique clinical entity

Davis AA, Behdad A, Viets Layng K, Wehbe F, Gerratana L, Mauer E, Barrett A, Shah AN, D’Amico P, Flaum L, Gradishar WJ, Platanias LC, Cristofanilli M. Washington University in St. Louis, St. Louis, MO; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Tempus Labs Inc., Chicago, IL; Centro di Riferimento Oncologico, Aviano, Italy.

 PD14-02 Unravelling spatial tumor organization and heterogeneity in lobular breast cancer using spatial transcriptomics

Laetitia Collet1, Matteo Serra1, Mattia Rediti1, Frédéric Lifrange2, David Venet1, XiaoXiao Wang1, Delphine Vincent1, Ghizlane Rouas1, Danai Fimereli1, David Gacquer1, Andrea Joaquin Garcia1, Isabelle Veys3, Ligia Craciun2, Denis Larsimont2, Miikka Vikkula4, François Duhoux5, Françoise Rothé1 and Christos Sotiriou1. 1Breast Cancer Translational Research, Intitut Jules Bordet, Brussels, Belgium2Laboratoire d’Anatomie Pathologique, Institut Jules Bordet, Brussels, Belgium3Department of Surgery, Institut Jules Bordet, Brussels, Belgium4Breast 5Human Molecular Genetics, de Duve Institute, Université Catholique de Louvaintranslational Research, Intitut Jules Bordet, Brussels, Belgium55Human Molecular Genetics, de Duve Institute, Université Catholique de Louvain, Brussels, Belgium

PD14-03 Genetic and epigenetic basis of invasive lobular carcinomas lacking CDH1-alterations

Fatemeh Derakhshan, Higinio Dopeso, Arnaud Da Cruz Paula, Pier Selenica, Antonio Marra, Edaise M da Silva, Andrea Gazzo, Shirin Issa Bhaloo, Dara S Ross, Anne Grabenstetter, Sarat Chandarlapaty, Pedram Razavi, Hannah Y. Wen, Hong Zhang, Edi Brogi, Britta Weigelt, Fresia Pareja and Jorge S. Reis-Filho. Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY

PD14-04 Circulating tumor DNA characterization of invasive lobular carcinoma in patients with metastatic breast cancer

Andrew A Davis1, Lorenzo Gerratana2, Katherine Clifton1, Marko Velimirovic3, Whitney L Hensing1, Ami N Shah2, Paolo D’Amico2, Carolina Reduzzi2, Qiang Zhang2, Charles S Dai3, Elyssa N Denault3, Nusayba A Bagegni1, Mateusz Opyrchal1, Foluso O Ademuyiwa1, Ron Bose1, William J Gradishar2, Amir Behdad2, Cynthia X Ma1, Aditya Bardia3 and Massimo Cristofanilli2. 1Washington University in St. Louis, St. Louis, MO;2Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL;3Massachusetts General Hospital, Boston, MA

PD14-05 Portraying tumor evolution of lobular breast cancer through phylogenetic analysis

Danai Fimereli1, David Venet1, Mattia Rediti1, David N Brown2, Bram Boeckx3, Marion Maetens4, Samira Majjaj1, Ghizlane Rouas1, Maria Capra5, Giuseppina Bonizzi5, Federica Contaldo5, Christine Galant6, Martine Piccart1, Giancarlo Pruneri7, Denis Larsimont1, Diether Lambrechts3, Christine Desmedt4, Françoise Rothé1 and Christos Sotiriou1. 1Institut Jules Bordet, Brussels, Belgium2Memorial Sloan Kettering Cancer Center, New York, NY;3VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium4Department of Oncology, KU Leuven, Leuven, Belgium5European Institute of Oncology, Milan, Italy6Cliniques Universitaires Saint Luc, Brussels, Belgium7Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

 PD14-06 Does chemotherapy benefit patients with HR+/HER2- invasive lobular breast cancer?

Yaghi M, Jabbal I, Bilani N, Zerdan MB, Elson L, Li H, Saravia D, Stone E, Nahleh Z. Cleveland Clinic Florida, Weston, FL; Cleveland Clinic Foundation, Cleveland, OH.

 PD14-07 Bromodomain and Extra-Terminal motif (BET) inhibitors are a rational therapeutic choice for treatment of invasive lobular carcinoma

Ward E, Blümel A, Conroy E, Cremin G, Gao B, Gallagher W, Cruz I, Hilakivi-Clarke L, Sflomos G, Brisken C, O’Connor D. RCSI, Dublin, Ireland UCD, Dublin, Ireland Lombardi Comprehensive Cancer Center, Washington DC , WA; Lombardi Comprehensive Cancer Center, Washington DC, WA; EPFL, Lausanne, Switzerland.

PD14-08 Effectiveness of aromatase inhibitors versus tamoxifen in lobular compared to ductal carcinoma: Individual patient data meta-analysis of 9328 women with central histopathology, and 7654 women with e-Cadherin status

Robert K Hills1, Steffi Oesterreich2, Otto Metzger3, David Dabbs2, Hongchao Pan1, Jeremy Braybrooke1, Richard Gray1, Richard Peto1, Rosie Bradley1, Ewan Straiton1, Richard Berry1, Daniel Rea4, David Cameron5, Jack Cuzick6, Meredith Regan3, Mitch Dowsett7, Ivana Sestak6, Jonas Bergh8, Sandra M Swain9, John Bartlett10, Early Breast Cancer Trialists’ Collaborative Group. 1University of Oxford, Oxford, United Kingdom2University of Pittsburgh, Pittsburgh, PA;3Dana Farber Cancer Institute, Boston, MA;4University of Birmingham, Birmingham, United Kingdom5University of Edinburgh, Edinburgh, United Kingdom6Wolfson Institute of Preventive Medicine, London, United Kingdom7Institute of Cancer Research, London, United Kingdom8Karolinska Institute, Stockholm, Sweden9Georgetown University, Washington, DC;10Ontario Institute for Cancer Research, Toronto, ON, Canada

 PD14-09 APOBEC signature, clinical characteristics, and outcome in hormone receptor-positive (HR+) HER2-negative (HER2-) breast cancer (BC) patients (pts) in real-world data (RWD)

Chumsri S, Raskina K, Sammons S, Alder L, Danziger N, Schrock AB, Kim McGregor K, Sokol E. Jacoby Center for Breast Health, Mayo Clinic, Jacksonville, FL; Foundation Medicine, Boston, MA; Department of Medicine, Duke University School of Medicine, Durham, NC; Oncocyte Corporation, Grand Junction, CO.

Other Poster Sessions with Posters Authored by SAB Members

Ongoing Trials Poster Session 1 – Wednesday, December 8, 2021: 5:00 pm – 6:30 pm CT

 OT1-10-01 The Breast Cancer Index registry study: A prospective multi-center observational study to evaluate patient outcome, clinical impact, and medication adherence in HR+ breast cancer patients considering treatment with extended endocrine therapy

 Joyce A O’Shaughnessy1, Jenny R Fox2, Carlos A Encarnación3, Brandon O’Neal4, Kai Treuner4, Tara Sanft5, Rachel C Jankowitz6, Mark D Pegram7, Catherine A Schnabel4 and Sami G Diab8. 1Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX;2Rocky Mountain Cancer Center, US Oncology, Boulder, CO;3Texas Oncology, US Oncology, Waco, TX;4Biotheranostics, Inc., San Diego, CA;5Yale School of Medicine, New Haven, CT;6University of Pennsylvania, Pittsburgh, PA;7Stanford Comprehensive Cancer Institute, Palo Alto, CA;8Rocky Mountain Cancer Center, US Oncology, Aurora, CO

 Poster Session 1 – Wednesday, December 8, 2021: 7:00 am – 8:30 am CT

 P1-02-09 Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer (ILC)

Maxim De Schepper1, Anne Vincent-Salomon2, Matthias Christgen3, Karen Van Baelen1, Hitoshi Tsuda4, Sasagu Kurozumi5, Maria Jose Brito6, Gabor Cserni7, Stuart Schnitt8, Denis Larsimont9, Janina Kulka10, Pedro Luis Fernandez11, Paula Rodriguez11, Ana Aula12, Cristina Mendelez12, Mieke Van Bockstal13, Aniko Kovacs14, Zsuzsanna Varga15, Jelle Wesseling16, Rohit Bhargava17, Pia Boström18, Camille Franchet19, Blessing Zambuko20, Gustavo Matute21, Anca Berghian22, Paul van Diest23, Steffi Oesterreich17, Patrick WB Derksen23, Giuseppe Floris24 and Christine Desmedt1. 1Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium2Diagnostic and Theranostic Medicine Division, Institut Curie, PSL Research University, Paris, France3Institute of Pathology, Hannover Medical School, Hannover, Germany4Department of Pathology, National Defense Medical College Hospital, Tokorozawa, Saitama, Japan5Department of Breast Surgery, International University of Health and Welfare, Chiba, Japan, Japan6Breast Unit, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal7Department of Pathology, Bács-Kiskun County Teaching Hospital, Kecskemét, Hungary8Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, MA;9Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium102nd Department of Pathology, Semmelweis University, Budapest, Pest, Hungary11Hospital German Trias i Pujol, Badalona, Spain12University Hospital Doctor Josep Trueta, Girona, Spain13Department of Pathology, Cliniques Universitaires Saint-Luc Bruxelles, Woluwé-Saint-Lambert, Belgium14Department of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden15Institut für Pathologie und Molekularpathologie, Universitätsspital Zürich, Zürich, Switzerland16Divisions of Molecular Pathology and Diagnostic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands17Women’s Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, PA;18Department of Pathology, Turku University Hospital and University of Turku, Turku, Finland19Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse – Oncopole, Toulouse, France20Department of Pathology, Sir Ketumile Masire Teaching Hospital, University of Botswana, Gaborone, Botswana21Clínica Universitaria Bolivariana, Universidad Pontificia Bolivariana, Medellín, Colombia22Département de biopathologie, Centre Henri Becquerel, Rouen, France23Department of Pathology, University Medical Center Utrecht, Utrecht, Netherlands24Department of Pathology, University Hospitals Leuven, UZ Leuven, Leuven, Belgium

 P1-05-03 Integrating spatial transcriptomics and high-resolution morphological annotation to investigate tumor heterogeneity and PAM50 molecular subtyping in lobular breast cancer

Matteo Serra1, Laetitia Collet1, Mattia Rediti1, Frédéric Lifrange2, David Venet1, Xiaoxiao Wang1, Delphine Vincent1, Ghizlane Rouas1, Danai Fimereli1, David Gacquer1, Andrea Joaquin Garcia1, Isabelle Veys3, Ligia Craciun2, Denis Larsimont2, Miikka Vikkula4, François Duhoux5, Françoise Rothé1 and Christos Sotiriou1. 1Breast Cancer Translational Research Laboratory J-C Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium2Laboratoire d’Anatomie Pathologique, Institut Jules Bordet, Université libre de Bruxelles, Brussels, Belgium3Department of Surgery, Institut Jules Bordet, Université libre de Bruxelles, Brussels, Belgium4Human Molecular Genetics, de Duve Institute, Université Catholique de Louvain, Brussels, Belgium5Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium

P1-08-13 Comparison of gene expression profiling results and clinical outcomes among patients with pleomorphic ILC and classic ILC

Marcus Dempster, Matthew Wright, Daniela Cocco, Ayat Elsherif, Stephanie A Valente, Hong Li and Megan L Kruse. Cleveland Clinic Foundation, Cleveland, OH

Poster Session 2 – Wednesday, December 8, 2021: 5:00 pm – 6:30 pm CT

P2-02-02 Differences in levels of circulating tumor cells (CTC) and disseminated tumor cells (DTC) in early-stage lobular versus ductal breast cancer

Silver Alkhafaji, Denise Wolf, Mark Magbanua, Laura Van ‘t Veer, John Park, Laura J. Esserman and Rita A. Mukhtar. University of California, San Francisco, San Francisco, CA

Poster Session 3 – Thursday, December 9, 2021: 7:00 am – 8:30 am CT

P3-01-25 Assessing the impact of preoperative breast MRI on time to treatment for invasive lobular carcinoma

Matthew D. Wright, Marcus S. Dempster, Ayat ElSherif, Daniela Cocco, Stephanie A. Valente, Hong Li and Megan L. Kruse. Cleveland Clinic, Cleveland, OH

Poster Session 5 – Friday, December 10, 2021: 7:00 am – 8:30 am CT

P5-12-03 Wcrc-25: A novel luminal invasive lobular carcinoma cell line model

Ashuvinee Elangovan1, Emily A Bossart1, Ahmed Basudan1, Nilgun Tasdemir1, Osama Shiraz Shah1, Kai Ding1, Carolin Meier1, Tanya Heim2, Lori Miller2, Tiantong Liu1, Shannon L Puhalla2, Grzegorz Gurda2, Peter C Lucas1, Priscilla F McAuliffe2, Jennifer M Atkinson1, Adrian V Lee1 and Steffi Oesterreich1. 1University of Pittsburgh, Pittsburgh, PA;2University of Pittsburgh Medical Center, Pittsburgh, PA

P5-04-02 Modulation of glucocorticoid receptor activity in invasive lobular carcinoma progression

Candace Frerich, Ishrat Durdana, Sumanta Chatterjee, Ariella Hanker, Lynda Bennett, Carlos L. Arteaga and Suzanne D. Conzen. UT Southwestern, Dallas, TX

We’re pleased to share the above research poster whose authors include our newest funded researcher Dr. Candace Frerich.

Spotlight Poster Discussion Session – Thursday, December 9, 2021: 5:00 pm – 6:30 pm CT

PD11-01 An artificial intelligence-based predictor of CDH1 biallelic mutations and invasive lobular carcinoma

Jorge S Reis-Filho1, Fresia Pareja1, Fatemeh Derakhshan1, David N Brown1, Jillian Sue2, Pier Selenica1, Yi Kan Wang2, Arnaud Da Cruz Paula1, Monami Banerjee2, Zahra Ebrahimzadeh2, Manuel Isava2, Matthew Lee2, Ran Godrich2, Adam Casson2, Ruben Padron2, George Shaikovski2, Alexander van Eck2, Antonio Marra1, Higinio Dopeso1, Hannah Y Wen1, Edi Brogi1, Matthew G Hanna1, Chris Kanan2, Jeremy D Kunz2, Felipe C Geyer2, Carla Leibowitz2, David Klimstra1, Leo Grady2 and Thomas J Fuchs3. 1Memorial Sloan Kettering Cancer Center, New York, NY;2Paige, New York, NY;3Icahn School of Medicine at Mount Sinai, New York, NY

PD11-02 Subtyping invasive carcinomas and high-risk lesions for machine learning based breast pathology

Matthew G Hanna1, Patricia Raciti2, Alican Bozkurt2, Ran Godrich2, Julian Viret2, Donghun Lee2, Philippe Mathieu2, Matthew Lee2, Eugene Vorontsov2, Tomer Sabo2, Felipe C Geyer2, Jorge S Reis-Filho1, Leo Grady2, Thomas Fuchs2 and Christopher Kanan2. 1MSKCC, New York, NY;2Paige, New York, NY

 SABCS 2021 is a hybrid conference. Posters and abstracts will be available virtually to registered attendees throughout the conference. The posters listed above are only a selection of all posters that are relevant to ILC. If you would like to explore the full list of posters, please visit the SABCS 2021 website.